ABX464-102

September 21, 2020September 21, 2020

ABX464 Effective at Keeping UC Patients in Remission Over Time, Data Show

News, Ulcerative colitis

ABX464, Abivax’s treatment candidate for ulcerative colitis (UC), continues to be safe and effective over time at keeping patients with moderate-to-severe UC in clinical remission, according to two-year data from a ... Read more

March 18, 2020March 18, 2020

Data from Abivax Trial Testing ABX464 Anti-inflammatory for UC Expected by Year’s End

News

Top-line data from an international Phase 2b clinical trial evaluating ABX464, Abivax’s lead therapeutic candidate for moderate-to-severe ulcerative colitis (UC), are expected later this year, according to the company’s financial ... Read more

June 17, 2019June 17, 2019

Nine-Month Results Show Continuing Efficacy of Abivax’s ABX464 in Extension Trial

News

Treatment with Abivax‘s ABX464 showed continuing effectiveness in ulcerative colitis patients, according to nine-month data of a maintenance clinical trial. The company is now recruiting people with moderate-to-severe ulcerative colitis ... Read more

January 4, 2019January 4, 2019

Abivax to Present Results of Trials of ABX464 as Ulcerative Colitis Therapy

News

Abivax will present the complete results of its Phase 2a trial ABX464-101 (NCT03093259) and interim results of the open-label extension study ABX464-102 (NCT03368118). Both aimed to assess the safety and efficacy of ABX464 as a treatment ... Read more

September 5, 2018September 5, 2018

Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial

News

Abivax‘s small, anti-inflammatory molecule ABX464 significantly increased clinical remission and mucosal healing over placebo in patients with moderate to severe active ulcerative colitis resistant to other therapies, top-line results from a ... Read more

January 8, 2018January 8, 2018

Belgium Approves Extension Trial of Abivax’s Ulcerative Colitis Therapy

News

Regulators in Belgium have approved Abivax’s request for a long-term extension of the company’s ongoing Phase 2a trial of ABX464 as a treatment for ulcerative colitis. It said it expects approvals from ... Read more